376 related articles for article (PubMed ID: 10375153)
1. Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study.
McHugo GJ; Drake RE; Teague GB; Xie H
Psychiatr Serv; 1999 Jun; 50(6):818-24. PubMed ID: 10375153
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Course of Clients With Co-occurring Schizophrenia-Spectrum and Substance Use Disorders in Urban Mental Health Centers: A 7-Year Prospective Study.
Drake RE; Luciano AE; Mueser KT; Covell NH; Essock SM; Xie H; McHugo GJ
Schizophr Bull; 2016 Jan; 42(1):202-11. PubMed ID: 26294706
[TBL] [Abstract][Full Text] [Related]
3. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.
Brunette MF; Noordsy DL; Xie H; Drake RE
Psychiatr Serv; 2003 Oct; 54(10):1395-401. PubMed ID: 14557527
[TBL] [Abstract][Full Text] [Related]
4. Evaluating use of continuous treatment teams for persons with mental illness and substance abuse.
Teague GB; Drake RE; Ackerson TH
Psychiatr Serv; 1995 Jul; 46(7):689-95. PubMed ID: 7552560
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders.
Clark RE; Teague GB; Ricketts SK; Bush PW; Xie H; McGuire TG; Drake RE; McHugo GJ; Keller AM; Zubkoff M
Health Serv Res; 1998 Dec; 33(5 Pt 1):1285-308. PubMed ID: 9865221
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic limit setting in an assertive community treatment program.
Neale MS; Rosenheck RA
Psychiatr Serv; 2000 Apr; 51(4):499-505. PubMed ID: 10737826
[TBL] [Abstract][Full Text] [Related]
7. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial.
Drake RE; McHugo GJ; Clark RE; Teague GB; Xie H; Miles K; Ackerson TH
Am J Orthopsychiatry; 1998 Apr; 68(2):201-15. PubMed ID: 9589759
[TBL] [Abstract][Full Text] [Related]
8. Fidelity and outcomes in six integrated dual disorders treatment programs.
Chandler DW
Community Ment Health J; 2011 Feb; 47(1):82-9. PubMed ID: 19771518
[TBL] [Abstract][Full Text] [Related]
9. [Personality disorders and substance abuse disorders. Psychosocial strategies].
Lana Moliner F
Actas Esp Psiquiatr; 2001; 29(1):58-66. PubMed ID: 11333520
[TBL] [Abstract][Full Text] [Related]
10. A multisite study of client outcomes in assertive community treatment.
McGrew JH; Bond GR; Dietzen L; McKasson M; Miller LD
Psychiatr Serv; 1995 Jul; 46(7):696-701. PubMed ID: 7552561
[TBL] [Abstract][Full Text] [Related]
11. Rural and urban differences in patients with a dual diagnosis.
Mueser KT; Essock SM; Drake RE; Wolfe RS; Frisman L
Schizophr Res; 2001 Mar; 48(1):93-107. PubMed ID: 11278157
[TBL] [Abstract][Full Text] [Related]
12. Assertive community treatment of severe mental illness: a Canadian experience.
Lafave HG; de Souza HR; Gerber GJ
Psychiatr Serv; 1996 Jul; 47(7):757-9. PubMed ID: 8807692
[TBL] [Abstract][Full Text] [Related]
13. An exploratory study of what clients like least about assertive community treatment.
McGrew JH; Wilson RG; Bond GR
Psychiatr Serv; 2002 Jun; 53(6):761-3. PubMed ID: 12045317
[TBL] [Abstract][Full Text] [Related]
14. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
Dixon L
Schizophr Res; 1999 Mar; 35 Suppl():S93-100. PubMed ID: 10190230
[TBL] [Abstract][Full Text] [Related]
15. Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders.
Drake RE; Xie H; McHugo GJ; Shumway M
Biol Psychiatry; 2004 Nov; 56(10):749-56. PubMed ID: 15556119
[TBL] [Abstract][Full Text] [Related]
16. Assertive community treatment versus usual care in engaging and retaining clients with severe mental illness.
Herinckx HA; Kinney RF; Clarke GN; Paulson RI
Psychiatr Serv; 1997 Oct; 48(10):1297-306. PubMed ID: 9323749
[TBL] [Abstract][Full Text] [Related]
17. Substance abuse in a Canadian population of Assertive Community Treatment (ACT) clients: implications for service planning and delivery.
Eastabrook S; Krupa T; Horgan S; Gerber G; Grant R; Mayo J; Leeder M; Stiemerling N
Can J Nurs Res; 2003 Mar; 35(1):44-51. PubMed ID: 12854240
[TBL] [Abstract][Full Text] [Related]
18. Client outcomes and the working alliance in assertive community treatment programs.
Calsyn RJ; Morse GA; Klinkenberg WD; Lemming MR
Care Manag J; 2004; 5(4):199-202. PubMed ID: 16294572
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and service utilization patterns of clients with schizophrenia-spectrum disorders in public residential detoxification settings.
Alvidrez J; Havassy BE
Community Ment Health J; 2006 Apr; 42(2):131-42. PubMed ID: 16425102
[TBL] [Abstract][Full Text] [Related]
20. Scope of agency control: assertive community treatment teams' supervision of consumers.
Moser LL; Bond GR
Psychiatr Serv; 2009 Jul; 60(7):922-8. PubMed ID: 19564222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
